Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment

27

Oct 2026

Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment

Patients with an advanced form of lung cancer lived 56 percent longer without their disease progressing when radiotherapy was added to the standard of care whole-body therapy, including chemotherapy and/or immunotherapy, according to initial results from a clinical trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.

Study establishes new perioperative standard in prostate cancer

27

Oct 2026

Study establishes new perioperative standard in prostate cancer

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide - a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.